Interferon Responses in Eczema Herpeticum
Completed
Conditions studied: Atopic Dermatitis, Eczema Herpeticum, Herpes Simplex Infections, Eczema Vaccinatum
In brief
Atopic dermatitis (AD) is a chronic skin disorder characterized by recurrent viral skin infections. A small subset of patients with AD suffer from disseminated viral infections, e.g., eczema herpeticum (ADEH+), after herpes simplex infection (HSV) or eczema vaccinatum (EV) after smallpox vaccination. Interferon gamma (IFNγ) plays a critical role in the innate and acquired immune responses by activating macrophages, enhancing natural killer cell activation, and promoting T cell differentiation, as well as regulating B cell isotype switching to immunoglobulin (Ig) G2a. Recent studies have demonstrated that IFNγ generation was significantly decreased after stimulation with HSV ex vivo. The purpose of this study is to determine if deficient IFNγ induction leads to susceptibility to HSV infection in ADEH+ patients.
Key facts
- Study ID
- NCT01429311
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 84
- Starts
- 2011-04-01
- Expected to finish
- 2016-01-01
- Last updated by the study team
- 2017-04-28
Who can join
Age: 6 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- National Jewish Health — Denver, Colorado, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.